Combined Therapy of Cyclophosphamide and Steroid on Progressive IgA Nephropathy.
- Author:
Sung Yeon CHO
1
;
So Young CHOI
;
Dong Young LEE
;
Ju Young MOON
;
Kyung Hwan JUNG
;
Sang Ho LEE
;
Tae Won LEE
;
Chun Kyu LIM
Author Information
1. Division of Nephrology, Department of Internal Medicine, Kyung hee University College of Medicine, Seoul Korea. freerocket@nate.com
- Publication Type:Original Article
- Keywords:
Cyclophosphamide;
Steroid;
IgA nephropathy
- MeSH:
Blood Pressure;
Creatinine;
Cyclophosphamide;
Follow-Up Studies;
Glomerulonephritis, IGA;
Humans;
Immunoglobulin A;
Kidney Failure, Chronic;
Proteinuria
- From:Korean Journal of Nephrology
2010;29(1):38-45
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: There were several reports showing that combined therapy of steroid and cyclophosphamide (PSL+CPA) was effective on progressive IgA nephropathy, but it remains inconclusive. METHODS: Patients with IgA nephropathy who showed more than 1.5 mg/dL of serum creatinine (SCr) and proteinuria and who were treated with the combined therapy in the Kyung hee University Hospital. RESULTS: The subjects were fifteen patients whose age was 40.3+/-10.8 yr, and the follow-up period was 39.1+/-24.6 months. Proteinuria levels declined from 4.08+/-2.58 g/gCr baseline to 1.80+/-1.72 g/ gCr 6 months after the treatment (p<0.0001). The comparison between the levels before & 6 months after the delta eGFR showed the improvement from -1.16+/-6.29 mL/min/1.73m2/month to 0.84+/-1.63 mL/ min/1.73m2/month (p=0.21), while these differences did not reach the level of statistical significance. According to delta eGFR, when the subjects were divided into the responder group (8 patients) and the non-responder group (7 patients), the former was 1.69+/-1.88 mL/min/1.73m2/month and the latter was -0.14+/-0.15 mL/min/1.73m2/month with significant difference (p=0.0014). According to UPCR, the responder group (12 patients) and the non-responder group (3 patients), systolic pressure, glomerulosclerosis and proteinuria after 6 months were significantly different (p=0.0115). Also, according to progressing ESRD, the CKD group (7 patients) and ESRD group (8 patients), age and SCr have shown a significant difference (p=0.0064). CONCLUSION: The combined therapy on progressive IgA nephropathy effectively reduced proteinuria and had protective effects on renal function in some patients. However, proteinuria and others were insufficient to be predictive factors on therapeutic responses. Large-scale prospective controlled studies may be necessary in the future.
